Register for our free email digests:
Division of Pfizer Inc.
Latest From Pfizer Ltd.
Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.
The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.
Following the decision by the UK competition authority to fine Pfizer and Flynn Pharma for “unfair and excessive” pricing, generic prices are to be brought under tighter government control. But it remains to be seen how these controls will be applied in practice where companies are suspected of excessive pricing, and exactly what might constitute an “unreasonable price,” say Gustaf Duhs and Astrid Arnold.
Appointments: Merck KGaA, Myovant, Scholar Rock, C4X Discovery, Paragon Bioservices and Gamida Cell.
This week's roundup includes appointments by Merck KGaA, C4X Discovery Holdings, Paragon Bioservices and board appointments by Scholar Rock, Myovant Sciences and Gamida Cell.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Ken Moran, Chmn. & Managing Dir.
Ian Read, Pres.
- Contact Info
Phone: (44) 1301 616161
Sandwich, CT13 9NJ
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.